How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Business Services · Forecast 2027–2033
Biological Therapies For Cancer Market
- By Therapy Type: Monoclonal Antibodies, Cancer Vaccines, Cytokines, Gene Therapy, Adoptive Cell Transfer
- By Cancer Indication: Lung Cancer, Breast Cancer, Colorectal Cancer, Melanoma, Leukemia, Lymphoma
- By Mechanism of Action: Immune Checkpoint Inhibitors, Tumor-Infiltrating Lymphocytes, Oncolytic Virus Therapy, Cytokine Therapy, CAR-T Cell Therapy
- By End User: Hospitals, Specialty Clinics, Cancer Research Institutes, Ambulatory Surgical Centers
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Monoclonal Antibodies leads By Therapy Type at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 15 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
11 chapters · 282 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.63 →
- 10 Competitive Landscape 5 sections p.169 →
- 11 Company Profiles 15 players: SWOT & benchmarking p.177 →
Full report · locked preview
Everything inside the Biological Therapies For Cancer Market report
A complete, evidence-based study - 11 chapters and 118 sections covering market size, segmentation across 4 axes, regional analysis and 15 company profiles, forecast to 2033.
Segmentation covered
Therapy Type 5
Cancer Indication 6
Mechanism of Action 5
End User 4
Companies profiled
Roche
Bristol-Myers Squibb
Novartis
Merck & Co.
Amgen
Pfizer
Johnson & Johnson
AstraZeneca
Gilead Sciences
Sanofi
Regeneron Pharmaceuticals
Celgene (a Bristol-Myers Squibb company)
+3 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
15 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Roche
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Bristol-Myers Squibb
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Novartis
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Merck & Co.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Amgen
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Pfizer
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →Johnson & Johnson
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.191 →AstraZeneca
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Gilead Sciences
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →Sanofi
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →Regeneron Pharmaceuticals
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →Celgene (a Bristol-Myers Squibb company)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →AbbVie
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →Moderna
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →BioNTech
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →
Global · 2025–2033
$1,933M by 2033 · 6.1% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Monoclonal Antibodies45.1
- Cancer Vaccines15.0
- Cytokines17.9
- Gene Therapy9.6
- Adoptive Cell Transfer12.5
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$397.1M → $716.6M · 7.7%
Europe$276.8M → $429.1M · 5.6%
Asia Pacific$252.7M → $394.9M · 5.7%
Latin America$156.4M → $263.2M · 6.7%
Middle East and Africa$120.3M → $214.4M · 7.5%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →6.052026
6.072027
6.092028
6.102029
6.102030
6.122031
6.132032
6.132033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Roche18.1
- Bristol-Myers Squibb22.1
- Novartis5.4
- Merck & Co.6.1
- Amgen9.3
- Pfizer11.0
- Others28.0
Segment contribution to growth (%)
Fig. 18 · p.39 →Therapy Type32.9%
Cancer Indication13.9%
Mechanism of Action20.5%
End User32.8%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America35.5
- Europe21.3
- Asia Pacific19.6
- Latin America13.0
- Middle East and Africa10.6
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Roche | 91 | 78 | 83 | 96 | 81 | 94 | 87 |
| Bristol-Myers Squibb | 70 | 77 | 77 | 77 | 74 | 82 | 76 |
| Novartis | 64 | 72 | 86 | 87 | 87 | 75 | 79 |
| Merck & Co. | 69 | 66 | 79 | 81 | 68 | 82 | 74 |
| Amgen | 63 | 60 | 65 | 76 | 56 | 69 | 65 |
| Pfizer | 59 | 47 | 57 | 70 | 49 | 63 | 58 |
| Johnson & Johnson | 53 | 58 | 51 | 64 | 43 | 59 | 55 |
| AstraZeneca | 47 | 54 | 37 | 52 | 39 | 45 | 46 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Roche
- Bristol-Myers Squibb
- Novartis
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Roche | ✓ | ✓ | ◐ | ✓ | ✓ | ✓ |
| Bristol-Myers Squibb | ◐ | ◐ | ◐ | ◐ | ◐ | ✓ |
| Novartis | − | ◐ | ◐ | ✓ | ✓ | ◐ |
| Merck & Co. | ◐ | − | ◐ | ◐ | ◐ | ✓ |
| Amgen | ◐ | ◐ | − | ✓ | − | ◐ |
| Pfizer | ◐ | − | ◐ | ◐ | − | − |
| Johnson & Johnson | − | ◐ | − | − | − | − |
| AstraZeneca | − | − | − | − | − | ◐ |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Roche87
2Novartis79
3Bristol-Myers Squibb76
4Merck & Co.74
5Amgen65
6Pfizer58
7Johnson & Johnson55
8AstraZeneca46
Competitive tiers
§8.4 · p.172 →Leader2
Set the pace on share, breadth and innovation.
RocheNovartis
Challenger2
Strong scale, closing on the leaders.
Bristol-Myers SquibbMerck & Co.
Contender2
Focused players with pockets of strength.
AmgenPfizer
Niche2
Specialists in a single segment or region.
Johnson & JohnsonAstraZeneca
Go-to-market strategy
Land Therapy Type in North America, then scale across Biological Therapies For Cancer Market — a $87M beachhead inside a $1.27B market.
Beachhead (SOM)$87Mobtainable near-term
Serviceable (SAM)$535Mreachable market
Primary motionDirect + partner-ledgo-to-market
Time to scale6 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion89 fit
Monoclonal Antibodies
Best fit — highest urgency & budget in Therapy Type.
Economic buyer79 fit
Cancer Vaccines
Strong fit — clear ROI and a fast path to value.
End user68 fit
Cytokines
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Therapy Type in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Cancer Indication & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + Mechanism of Action
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales44%
Partner / channel28%
Digital / self-serve21%
Marketplaces7%
Positioning & messaging
§GTM 2 · p.194 →For Therapy Type leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Biological Therapies For Cancer Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified42%
Sales qualified23%
Evaluation13%
Closed-won6%
$12.3KCAC
$44KLTV
3.5:1LTV : CAC
< 4 moCAC payback
Investment thesis
Biological Therapies For Cancer Market is a resilient opportunity — $6.28B by 2033, compounding at 3.6%.
TAM · 2025$4.75Btoday
TAM · 2033$6.28Bforecast
CAGR3.6%2027–2033
Cumulative$49.3Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$6.28BTotal addressable market
SAM$2.31BServiceable available market
SOM$393MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →3.6% CAGR
Demand compounds through 2033, outpacing GDP across Therapy Type.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Therapy Type moving from early to mainstream — durable secular demand.
Consolidation upside
15+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$6.28BLarge & growingTAM by 2033 at 3.6% CAGR
$2.31BServiceable nowreachable with today’s model
$393MBeachhead winobtainable near-term share
15+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$4.90BBear2.3% CAGR
$6.28BBase3.6% CAGR
$8.03BBull4.7% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Cancer Indication optionality
- Customer concentrationBroaden installed base beyond top accounts
Board pack · executive summary
Biological Therapies For Cancer Market — a $7.59B market by 2033. Plan: grow share from 8.6% to 17.4%.
Market size · 2033$7.59Btotal addressable
Market CAGR5.3%2027–2033
Target share17.4%from 8.6% today
Revenue ambition$1.32Bby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 8.6% | 17.4% | At risk |
| Revenue | $663M | $1.32B | On track |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | On track |
| Segment coverage | 2 of 4 axes | 4 of 4 axes | At risk |
| Gross margin | 28.0% | 39.5% | On track |
| Customer retention | 85.0% | 93.1% | On track |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Therapy Type
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Cancer Indication capability
A defensible second engine — invest in Cancer Indication to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Therapy Type share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Cancer Indication
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $170M capacity & capability investment
- Greenlight bolt-on M&A in Cancer Indication
- Authorise North America expansion plan
- Fund R&D program for Therapy Type leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownBehind
- Competitive share lossOn track
- Input-cost & supply riskAt risk
- Regulatory / policy changeAt risk
- Execution & talentOn track
Sales deck · value proposition
Win the Biological Therapies For Cancer Market conversation — a $7.08B market you can size, segment and defend in minutes.
Market size · 2033$7.08Btotal opportunity
Growth9.3%CAGR to 2033
Addressable buyers1,377+accounts in scope
Typical ROI5.9×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Therapy Type
Goal Grow share in Therapy Type
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →5.9×return on cost, year one
< 2 mopayback period
$54K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
15+players profiled in this market
Coverage includes
RocheBristol-Myers SquibbNovartisMerck & Co.AmgenPfizerJohnson & JohnsonAstraZeneca+7 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Biological Therapies For Cancer Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Biological Therapies For Cancer Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Business Services · scroll →Biological Therapy Market
Market size, share, segmentation and regional forecast.
$3.5B market · 2025 base year
View reportBiological Uncoiling Reagent Market
Market size, share, segmentation and regional forecast.
$1.8B market · 2025 base year
View reportBiological Workbench Market
Market size, share, segmentation and regional forecast.
$1.1B market · 2025 base year
View reportBiologicals In Oncology Drug Market
Market size, share, segmentation and regional forecast.
$4.1B market · 2025 base year
View reportBiologics and Biosimilar Market
Market size, share, segmentation and regional forecast.
$4.5B market · 2025 base year
View reportBiologics Clinical Manufacturing CDMO Service Market
Market size, share, segmentation and regional forecast.
$3.6B market · 2025 base year
View reportBiologics Drug Market
Market size, share, segmentation and regional forecast.
$1.9B market · 2025 base year
View reportBiologics Fill Finish CDMOs Market
Market size, share, segmentation and regional forecast.
$3.9B market · 2025 base year
View reportBiologics for Animal Health Market
Market size, share, segmentation and regional forecast.
$1.2B market · 2025 base year
View reportBiologics Manufacturing Market
Market size, share, segmentation and regional forecast.
$3.7B market · 2025 base year
View reportBiomarker (Medicine) Market
Market size, share, segmentation and regional forecast.
$2.7B market · 2025 base year
View reportBiomarkers Validation and Testing Market
Market size, share, segmentation and regional forecast.
$3.9B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report ships as a formatted PDF, a fully editable XLSX containing all underlying data tables, and a presentation-ready PPT deck - so you can re-chart, re-model, or drop any figure straight into your own deck.